← Eichor
Condition: Liver Steatoses Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Liver Steatoses

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Li
Phase N/A · 2 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT07652892Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
Phase N/A · 1 location(s) · Steno Diabetes Center Copenhagen · NCT05890365BeijngFH Health Cohort Study
Phase N/A · 1 location(s) · Beijing Friendship Hospital · NCT05546086Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese
Phase N/A · 1 location(s) · Ruijin Hospital · NCT05870969Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Phase N/A · 1 location(s) · Mayo Clinic · NCT04232566Prevalence of NAFLD in T1DM Patients
NA · 1 location(s) · Ziekenhuis Oost-Limburg · NCT06445361Evaluation of Risk of hEpatocellular Carcinoma
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT06523179Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With
NA · 2 location(s) · Catholic University of the Sacred Heart · NCT06801769Liver Damage and Cardiometabolic Disorders in NAFLD
Phase N/A · 1 location(s) · University of Roma La Sapienza · NCT04036357Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
NA · 1 location(s) · Henry Ford Health System · NCT07646197Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
Phase 2 · 8 location(s) · Cascade Pharmaceuticals, Inc · NCT07198386Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
NA · 1 location(s) · Phenomen Pharma · NCT07068191A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Phase 2 · 5 location(s) · Regeneron Pharmaceuticals · NCT07527910Lifestyle Modification in the Treatment of NAFLD.
NA · 1 location(s) · General University Hospital, Prague · NCT05816915Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Phase 4 · 1 location(s) · Seoul National University Bundang Hospital · NCT06989723Implementing Food Referrals for Equity and Sustained Health
Phase 2 · 2 location(s) · University of California, San Diego · NCT06661538Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
NA · 1 location(s) · Uppsala University · NCT06701968NASH AMPK Exercise Dosing (AMPED) Trial
NA · 1 location(s) · Milton S. Hershey Medical Center · NCT04987879Efficacy and Safety of Rifaximin in Treating MAFLD
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07185932HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)
Phase 2 · 20 location(s) · Tasly Pharmaceutical Group Co., Ltd · NCT05632861Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Phase 2 · 13 location(s) · National Institute of Diabetes and Digestive and Kidney Dise · NCT05832229Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
Phase N/A · 1 location(s) · Chungnam National University Hospital · NCT06519162Effect of Timed-Restricted Eating on Metabolic Health
NA · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT06061042Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features
NA · 1 location(s) · Chinese University of Hong Kong · NCT05334836Blood Collection Biorepository for Liver Disease Research
Phase N/A · 1 location(s) · State University of New York at Buffalo · NCT03025074Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
NA · 1 location(s) · Stanford University · NCT05165706CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05623150Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813508A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Phase 1 · 3 location(s) · GlaxoSmithKline · NCT07358546Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06879236
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.